131I治疗Graves病的效果以及对A-TPO、TRAb水平的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of 131 I treatment on patients with diffuse toxic goiter(Graves′disease)and its influence on the levels of antithyroid peroxidase antibody (A-TPO)and thyrotropin receptor antibody(TRAb).Methods From July 2015 to January 2017,100 patients with Graves′disease were selected and divided into control group and experimental group with 50 patients in each group by random number table method.The control group was treated with ATD while the experimental group was treated with 131I.The TSH,A-TPO,TRAb levels,thyroid quality,clinical efficacy and total incidence of adverse reactions were compared between the two groups.Results After treatment,the TSH levels of the two groups were higher than those before treatment,and the levels of A-TPO and TRAb were lower than those before treatment.the differences were statistically significant(P<0.05).The levels of A-TPO and TRAb in the experimental group were lower than those in the control group,the difference was statistically significant(P<0.05).There was no significant difference in thyroid quality between the two groups before and after treatment(P>0.05).The total effective rate of the experimental group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the experimental group was significantly lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion Graves′disease patients receiving 131I treatment has good clinical effect,and can effectively improve the patient′s A-TPO,TRAb levels,and is safe and effective,worthy of clinical promotion.

Key words： Graves&prime disease 131I')" href="#">131I Effect A-TPO TRAb

	Service

	E-mail this article 131I;Effect;A-TPO;TRAb”. Please open it by linking:http://dangdaiyiyao.com/EN/abstract/abstract5611.shtml" name="neirong">
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LAN Hao
	LIWen-bin
	CHEN Qin

Cite this article:

LAN Hao,LIWen-bin,CHEN Qin. Effect of 131I on Graves′disease and its influence on A-TPO and TRAb levels[J]. 中国当代医药, 2018, 25(24): 69-71.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I24/69

[1]	郭泽华，于世鹏，班博，等.Graves病患者131I、甲巯咪唑治疗前后外周血Th17细胞及IL－17水平的变化[J].中国免疫学杂志，2015，31（1）：117-121.
[2]	黄诚，张治业，邓淼，等.预先使用抗甲状腺药物对放射性131I治疗Graves病患者治愈时间的影响[J].中国全科医学，2016，19（33）：4056-4060.
[3]	徐金娥，彭秋菊，邓波，等.131I治疗Graves病的预后评估及对A-TPO、TRAb和IL-17水平的影响[J].华中科技大学学报（医学版），2015，36（1）：110-113.
[4]	杨静，潘天荣，杜益君，等.Graves病131I或抗甲状腺药物治疗前后外周血CD4+CD25+CD127low调节性T细胞的变化[J].安徽医科大学学报，2016，51（5）：691-695.
[5]	马玲.低剂量131I对Graves病患者血清Ghrelin水平及相关血清学指标的影响研究 [J].重庆医学，2015，44（32）：4529-4531.
[6]	卢健祥，袁卫娟，陈亮明，等.131I治疗前后初诊毒性弥漫性甲状腺肿患者血清CXC趋化因子配体10、白细胞介素6水平的变化及意义[J].中国医院用药评价与分析，2016，16（7）：902-904.
[7]	窦家庆，荚静芳.Graves病患者131碘治疗后甲状腺相关抗体的变化及意义[J].安徽医药，2015，19（12）：2377-2378，2379.
[8]	马玉波，顾爱春，徐枫，等.基于个体化131I剂量率治疗Graves′病[J].复旦学报（医学版），2016，43（3）：324-327.
[9]	马学芹，于世鹏.初发Graves病患者131I治疗前后IL-23/Th17轴相关因子水平的变化及意义[J].中国免疫学杂志，2013，29（7）：733-735，754.
[10]	马燕.131I治疗Graves病对血清TRAb、TGAb和TPOAb的影响及其临床意义[J].中国煤炭工业医学杂志，2015，18（6）：950-953.
[11]	王任飞，谭建，张桂芝，等.2125例甲状腺功能亢进患者131I治疗的回顾性分析[J].中华内分泌代谢杂志，2015，31（5）：421-426.
[12]	张海三，张红星，刘保平，等.Graves病患者131I治疗后疾病影响程度与生活质量变化[J].中华行为医学与脑科学杂志，2014，23（10）：904-908.
[13]	张庆，邵毅，关晏星，等.标准剂量泼尼松联合谷氨酰胺对131I治疗后 Graves眼病的保护作用[J].重庆医学，2017，46（13）：1775-1778.
[14]	石丽红，蒋宁一，孙云凤，等.格雷夫斯甲亢合并白细胞减少患者131I治疗临床分析[J].中华核医学与分子影像杂志，2013，33（2）：120-123.
[15]	黄际远，宋文忠，戴庆靖，等.中老年Graves甲亢的临床特点及131I碘的治疗效果[J].中国老年学杂志，2013，33（23）：5832-5834.